» Articles » PMID: 30246063

A Moderate Form of Osteogenesis Imperfecta Caused by Compound Heterozygous Mutations

Overview
Journal Bone Rep
Date 2018 Sep 25
PMID 30246063
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Osteogenesis imperfecta (OI) is a genetic disorder causing skeletal fragility, multiple fractures, and other extraskeletal manifestations. Most cases are caused by mutations in or . Recent investigations have discovered several other autosomal recessive genes responsible for OI. Among these genes is , which is involved in post-translational modifications of collagen. To date, more than 40 mutations have been described. One of these mutations is carried by 1.5% of West Africans and 0.4% of African Americans, and is associated with OI Type VIII. We describe the case of a five year old male with a moderate form of OI and compound heterozygous LEPRE1 mutations (c.1080 + 1G > T; c.1646 T > G, p.Met549Arg). He was diagnosed shortly after birth following a skeletal survey demonstrating multiple healing fractures as well as lower extremity deformity suggestive of remote fractures. He was then without a fracture until a calvarial fracture at 18 months of age, a femur fracture at 4 years and seven months and a second femur fracture at 5 years and 4 months. He walked at age 14 months and has been an active boy. Pamidronate infusions began at seven weeks of age and were discontinued at three years of age due to increased bone mineral density and absence of fractures. Type VIII OI typically causes a severe to lethal phenotype presenting at birth with severe osteopenia, congenital fractures and other clinical manifestations. Only a few individuals have survived to childhood. This case description serves to expand the clinical phenotyping of this recessive form of OI into the more moderate spectrum.

Citing Articles

Milder presentation of osteogenesis imperfecta type VIII due to compound heterozygosity for a predicted loss-of-function variant and novel missense variant in -further expansion of the phenotypic spectrum.

Mikhail K, Vansickle E, Rossetti L Cold Spring Harb Mol Case Stud. 2023; 9(1).

PMID: 36963805 PMC: 10111797. DOI: 10.1101/mcs.a006260.


Phenotypic Variation in Vietnamese Osteogenesis Imperfecta Patients Sharing a Recessive Pathogenic Variant.

Zhytnik L, Duy B, Eekhoff M, Wisse L, Pals G, Reimann E Genes (Basel). 2022; 13(3).

PMID: 35327962 PMC: 8950175. DOI: 10.3390/genes13030407.

References
1.
Willaert A, Malfait F, Symoens S, Gevaert K, Kayserili H, Megarbane A . Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet. 2008; 46(4):233-41. DOI: 10.1136/jmg.2008.062729. View

2.
Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

3.
Barnes A, Chang W, Morello R, Cabral W, Weis M, Eyre D . Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006; 355(26):2757-64. PMC: 7509984. DOI: 10.1056/NEJMoa063804. View

4.
Glorieux F, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339(14):947-52. DOI: 10.1056/NEJM199810013391402. View

5.
Morello R, Bertin T, Chen Y, Hicks J, Tonachini L, Monticone M . CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006; 127(2):291-304. DOI: 10.1016/j.cell.2006.08.039. View